LORRAIN DANIEL S. (Chief Scientific Officer) sold 0.1% of their position (100.00 shares) of CONTINEUM THERAPEUTICS, INC. on the open market
Open‑market sale worth $1.6K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/20/2026ACC: 0001437749-26-004912
Officer· Chief Scientific Officer
Since Mar 2026
-100.00
Net shares
Net seller
$1.6K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
100.00 acquired · 200.00 disposed
Non-Derivative Transactions2
Class A Common Stock
Direct
Shares
+100.00
Price / share
$1.01
Trade value
$101.00
% of position
0.1%
2/19/2026
156.05K→156.15K
Class A Common Stock
Direct
Shares
−100.00
Price / share
$16.00
Trade value
$1.60K
% of position
0.1%
2/19/2026
156.15K→156.05K
Total
Net shares
+0.00
Net value
-$1.50K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock Direct | 2/19/2026 | M · Option Exercise | +100.00 | $1.01 | $101.00 | 0.1% | 156.05K | 156.15K |
| Class A Common Stock Direct | 2/19/2026 | S · Sale | −100.00 | $16.00 | $1.60K | 0.1% | 156.15K | 156.05K |
| Total | +0.00 | -$1.50K | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Class A Common Stock
100.00 shares
Shares
−100.00
Strike price
1.01
Held after
75.43K
Exercisable
—
2/19/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Class A Common Stock100.00 shares | 2/19/2026 | M · Option Exercise | −100.00 | 1.01 | — | 75.43K |
Non-Derivative Holdings (Post-Transaction)1
Class A Common Stock
IndirectShares owned6.84K
Total
6.84K indirect6.84K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Class A Common Stock | 6.84K | Indirect |
| Total | 6.84K | 6.84K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported